Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Accured Expenses: 2011-2024

Historic Change in Accured Expenses for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$33.3 million.

  • Ptc Therapeutics' Change in Accured Expenses fell 236.17% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 2142.47%. This contributed to the annual value of -$33.3 million for FY2024, which is 168.92% down from last year.
  • According to the latest figures from FY2024, Ptc Therapeutics' Change in Accured Expenses is -$33.3 million, which was down 168.92% from $48.3 million recorded in FY2023.
  • Ptc Therapeutics' Change in Accured Expenses' 5-year high stood at $72.0 million during FY2020, with a 5-year trough of -$33.3 million in FY2024.
  • For the 3-year period, Ptc Therapeutics' Change in Accured Expenses averaged around $14.2 million, with its median value being $27.5 million (2022).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 168.16% in 2020, then slumped by 168.92% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Change in Accured Expenses (Yearly) stood at $72.0 million in 2020, then plummeted by 36.55% to $45.7 million in 2021, then slumped by 39.68% to $27.5 million in 2022, then soared by 75.54% to $48.3 million in 2023, then slumped by 168.92% to -$33.3 million in 2024.